Moderna and Merck Push Personalized Lung Cancer Vaccine Into Phase 3

Moderna (MRNA) announced an update on their ongoing clinical study.

Moderna and Merck Advance Personalized Lung Cancer Vaccine Trial

The Phase 3 study “INTerpath-014” tests an adjuvant approach in high-risk stage I non-small cell lung cancer after surgery. It aims to see if adding intismeran, a personalized mRNA cancer vaccine, with or without an immune therapy mix can keep the disease from coming back. The trial is important because it explores a new way to cut relapse risk in early lung cancer.

The study tests three setups. One uses intismeran plus a subcutaneous form of pembrolizumab combined with berahyaluronidase alfa, and another uses intismeran alone, both compared to placebo. Intismeran is built to train the immune system to recognize a patient’s tumor, while the combo shot is meant to boost that immune response in a convenient injection form.

The trial is a randomized Phase 3 test where people are assigned to different arms by chance. It uses a parallel design, meaning all groups are treated and followed at the same time, and most arms are double blind so neither patients nor key study staff know if they get real drug or placebo. The main goal is treatment, measured by how long patients stay free of disease after surgery.

The study was first submitted on April 1, 2026, marking the formal start of trial planning and site activation. It is currently listed as recruiting, which signals that centers are enrolling patients and that the program is moving into full execution. The latest update on May 13, 2026, confirms ongoing adjustments and oversight as the sponsors refine study details.

For investors, this update underlines the strategic push by Moderna and Merck into early-stage lung cancer. Positive data in the future could support a major new revenue stream in adjuvant oncology, and strengthen the thesis around mRNA cancer vaccines beyond COVID-19. It also raises competitive pressure on other immunotherapy players in NSCLC that lack a personalized vaccine angle.

The recruitment status and fresh update should support sentiment that the program is on track, though it also signals a long road to readouts and regulatory risk. Near term, share price impact for MRNA and MRK may be modest, as this is an early process milestone rather than data-driven. The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about MRNA’s potential, visit the Moderna drug pipeline page.